VT-CANNATROL
25.4.2024 14:04:26 CEST | Business Wire | Press release
Cannatrol, the creators of the only total dry, cure and store system for the cannabis industry, announced today the approval of two European patents for its Vaportrol® Technology, protecting the proprietary technology throughout the European Union.
“As the European cannabis industry grows, demand for precision drying, curing and storage technologies continues to expand,” said David Sandelman, co-founder, COO and CTO of Cannatrol. “Cannatrol’s proven environmental-control system ensures top-quality cannabis through a repeatable, consistent process, and it’s appropriate for any scale of cultivation, from large-scale greenhouse production to home growers.”
Cannatrol’s patented postharvest technology is proven to increase yields and curing efficiency, and delivers on average 16% higher terpene retention when compared to traditional drying and curing methods, according to independent testing by The Cannabis Research Coalition. Throughout drying, curing and storage, the environment will stay consistent and repeatable no matter the season, climate or geographic location.
“We have already seen exponential growth in the U.S. as commercial cultivators experience the benefits Cannatrol systems offer for their bottom line, overall efficiency and, most importantly, their product quality,” said Jane Sandelman, CEO and Co-Founder of Cannatrol. “Cultivators in the European Union will now be able to develop standard operating procedures that leave nothing to chance, producing flower that is never over-dried and has a longer shelf life.”
Rather than rely on guesswork, Cannatrol utilizes science, water activity and vapor pressure, leading to elevated product quality, increased yields, Good Manufacturing Processes (GMP) compliance and bottom line improvement. These patents extend beyond cannabis as Vaportrol® Technology has been proven and utilized in the U.S. and European meat and cheese industries for years.
Cannatrol has held a U.S. patent since 2020 and began the process of obtaining European patents in January of 2019. All production will remain in the U.S., however, the patented Vaportrol® Technology equipment will be shipped to eligible countries in the European Union.
To learn more about Cannatrol and the Vaportrol® Technology, please visit cannatrols.com.
About Cannatrol
Cannatrol Systems, developed by VT Dry & Cure Technologies, Inc, supports commercial and home grow cannabis cultivation by streamlining and tightly controlling the critical drying and curing processes as well as postharvest storage. With patented Vaportrol® Technology, the system controls water loss by regulating the vapor pressure and ensures the correct final water activity, critical for terpene preservation, maximized potency, increased yield and premium quality. Cannatrol’s environmental control solution ensures consistent results for every climate and geography, taking the guesswork and the risk out of seasonal humidity and temperature swings. No other postharvest solution offers this unique and advanced technology. The proprietary technology has earned VT Dry & Cure Technologies a spot on the coveted 2024 Forbes 42.0 List. Learn more at cannatrols.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240425990195/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen Announces FDA IND Clearance for Partner NEOK Bio’s NEOK002 Targeting Solid Tumors27.3.2026 01:00:00 CET | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that its partner NEOK Bio, Inc. recently received clearance from the U.S. Food and Drug Administration (FDA) of an investigational new drug (IND) application for NEOK002, an EGFR/MUC1-targeting ADC program for solid tumors. NEOK Bio plans to initiate a Phase 1 clinical study in the second quarter of 2026 and expects to report initial data in 2027. This IND clearance marks an important milestone for NEOK002, an EGFR/MUC1-targeting ADC candidate developed by NEOK Bio and built on a bispecific antibody originally developed by Biocytogen and licensed in 2024. According to NEOK Bio, NEOK002 is being advanced for solid tumors and may offer differentiated efficacy and safety compared with monospecific ADC approaches directed at either target alone. Dr. Yuelei Sh
Spring is in Full Bloom at the Empire State Building with New Festive Experiences, Sweet Treats, and Seasonal Tower Lighting26.3.2026 21:30:00 CET | Press release
Spring is in full swing at the “World’s Most Famous Building.” The Empire State Building (ESB) today announced a vibrant lineup of spring events in NYC, which include special experiences, treat pop-ups, and an iconic tower lighting that captures the joy and color of the beautiful season. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260326216271/en/ Spring is in Full Bloom at the Empire State Building with New Festive Experiences, Sweet Treats, and Seasonal Tower Lighting “The Empire State Building Observation Deck has transformed into a celebration of the season and one of the best things to do in NYC this spring,” said Dan Rogoski, observatory general manager. “Whether it’s views beside our butterfly installation, sweet pop-ups, or a chance to spot the Easter Bunny, there is something special for every visitor.” Flutter of Color: The Empire State Building installed a brand-new photo opportunity on the 86th Floor Observati
Venture Global and Edison Announce Calcasieu Pass Arbitration Settlement26.3.2026 21:15:00 CET | Press release
Today, Venture Global and Edison jointly announced the signature of a commercial agreement for the settlement of the pending arbitration between the two companies concerning the Calcasieu Pass project. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260326559130/en/ Completion of the settlement is expected by the end of Q2 2026, at which point the arbitration will be terminated. The agreement fully resolves the arbitration in its entirety. As part of the settlement, Edison and Venture Global have also agreed to the delivery to Europe of additional cargoes beyond those envisaged under the long-term contract, to support gas supplies primarily to the Italian market. The first delivery is scheduled for May 2026, in Italy, at the Adriatic LNG Terminal. The agreement represents a significant step in strengthening commercial cooperation between the parties and it establishes a foundation for further future deliveries in the context
Reply Recognized as a Microsoft Frontier Partner for Enterprise AI Delivery26.3.2026 19:06:00 CET | Press release
Reply [EXM, STAR: REY] announces it has been recognized as a Microsoft Frontier Partner within the Microsoft AI Cloud Partner Program, earning the Frontier Partner Badge for demonstrating advanced capabilities in delivering AI-first solutions across Cloud & AI Platforms, AI Business Solutions, and Security. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260326965586/en/ The recognition reflects Reply’s capabilities across the Microsoft ecosystem, built through the work of its specialized companies – including Aim Reply, Business Elements Reply, Cluster Reply, Root16 Reply, Solidsoft Reply, Valorem Reply, WM Reply and Zest Reply – supporting enterprise organizations in designing, implementing, and operating AI solutions on Microsoft platforms across real-world business scenarios. The Frontier Partner badge recognizes partners that demonstrate advanced AI driven capabilities and meet rigorous badge requirements at the time of
SLB Announces Dates for First-Quarter 2026 Results Conference Call26.3.2026 18:00:00 CET | Press release
SLB (NYSE:SLB) will hold a conference call on April 24, 2026, to discuss the results for the first quarter ending March 31, 2026. The conference call is scheduled to begin at 11:00 a.m. US Eastern time and a press release regarding the results will be issued at 7:00 a.m. US Eastern time. To access the conference call, listeners should contact the Conference Call Operator at +1 (833) 470-1428 within North America or +1 (404) 975-4839 outside of North America approximately 10 minutes prior to the start of the call and the access code is 742955. A webcast of the conference call will be broadcast simultaneously at https://events.q4inc.com/attendee/972985185 on a listen-only basis. Listeners should log in 15 minutes prior to the start of the call to test their browsers and register for the webcast. Following the end of the conference call, a replay will be available at www.slb.com/irwebcast until May 1, 2026, and can be accessed by dialing +1 (866) 813-9403 within North America or +1 (929)
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
